State of Health

State of Health

Share this post

State of Health
State of Health
Pitavastatin as a Potential Intervention for Cardiovascular Disease in HIV Infection
Copy link
Facebook
Email
Notes
More

Pitavastatin as a Potential Intervention for Cardiovascular Disease in HIV Infection

A clinical trial suggests pitavastatin could reduce cardiovascular disease risk in HIV patients.

Medzcool's avatar
Medzcool
Sep 01, 2023
∙ Paid

Share this post

State of Health
State of Health
Pitavastatin as a Potential Intervention for Cardiovascular Disease in HIV Infection
Copy link
Facebook
Email
Notes
More
Share

TL;DR

A new phase 3 clinical trial suggests that pitavastatin may help reduce the risk of cardiovascular disease (CVD) in HIV patients, who have a higher risk than the general population. The trial involved 7769 participants on antiretroviral therapy and showed a lower incidence of major adverse cardiovascular events in the pitavastatin group after a median follow-up of 5.1 years. Though there were muscle-related complications and instances of diabetes mellitus, the significant hazard ratio indicates a 35% lower risk of CVD events in the pitavastatin group. While promising, more research is needed to confirm these findings and to determine if pitavastatin should become a standard part of HIV patient care.

Keep reading with a 7-day free trial

Subscribe to State of Health to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 State of Health
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More